Drugs / Tdap
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05662852 | May 2023 → May 2025 | — | ABO Holdings, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tdap | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05662852 ↗ |
| Modality | Vaccine | “Tdap vaccine” NCT05662852 ↗ |
| Route | Intramuscular | “Route: Intramuscular (IM) in the deltoid muscle” NCT05662852 ↗ |